ConductScience.org, home
GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)
API referenceFor AI assistants

Trial · NCT01419665

Results by group26

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 26

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Overall Response Rate (ORR)GP201387.190% Confidence Interval 83.59 to 90.15percentage
Overall Response Rate (ORR)Rituximab87.590% Confidence Interval 84.04 to 90.49percentage
To Evaluate the Complete Response (CR) Rate During the Combination Treatment PeriodGP201346Participants
To Evaluate the Complete Response (CR) Rate During the Combination Treatment PeriodRituximab42Participants
To Evaluate the Partial Response (PR) Rate During the Combination Treatment PeriodGP2013225Participants
To Evaluate the Partial Response (PR) Rate During the Combination Treatment PeriodRituximab232Participants
To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post RandomizationGP201397Participants
To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post RandomizationRituximab78Participants
To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of DeathsGP201329Participants
To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of DeathsRituximab31Participants
To Evaluate the Incidence of Immunogenicity (ADA Formation) Against GP2013 and MabThera (Rituximab)GP2013end of treatment combination phase (24 weeks)1Participants
To Evaluate the Incidence of Immunogenicity (ADA Formation) Against GP2013 and MabThera (Rituximab)Rituximabend of treatment combination phase (24 weeks)2Participants
To Evaluate the Incidence of Immunogenicity (ADA Formation) Against GP2013 and MabThera (Rituximab)GP2013end of treatment manintenance phase (3 years)1Participants
To Evaluate the Incidence of Immunogenicity (ADA Formation) Against GP2013 and MabThera (Rituximab)Rituximabend of treatment manintenance phase (3 years)0Participants
To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Max)GP2013333.59Geometric Coefficient of Variation 41.09microg/mL
To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Max)Rituximab331.93Geometric Coefficient of Variation 35.32microg/mL
To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Trough)GP201366.42Standard Deviation 47.593microg/mL
To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Trough)Rituximab82.13Standard Deviation 61.526microg/mL
To Evaluate a PD Marker (Peripheral CD19+ B-cell Counts) Following the Treatment With GP2013 + Chemotherapy Amd MabThera- ChemotherapyGP20131790Geometric Coefficient of Variation 23.5%*day
To Evaluate a PD Marker (Peripheral CD19+ B-cell Counts) Following the Treatment With GP2013 + Chemotherapy Amd MabThera- ChemotherapyRituximab1910Geometric Coefficient of Variation 13.3%*day

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01419665/results

API referenceFor AI assistants